Why is this study important?  

This study addresses a critical gap in treatment for high-surgical-risk patients with symptomatic aortic regurgitation (AR), a population previously without a dedicated transcatheter aortic valve replacement (TAVR) option. The JenaValve Trilogy™ offers a tailored solution, demonstrating favorable hemodynamic outcomes, improved quality of life, and sustained LV remodeling. If approved, it could establish a new standard of care for this high-risk population. 

Should I change my practice because of these findings?  

Not yet. While the results are promising, the Trilogy THV system is currently investigational and not yet FDA-approved in the U.S. Additionally, clinical evidence shows excellent outcomes in terms of safety, mortality reduction, and functional improvement at 2 years, but widespread adoption depends on regulatory FDA approval. 

What question was the study supposed to answer?   

The ALIGN-AR trial aimed to evaluate: 

• Whether the Trilogy THV system is a safe and effective option for patients with ≥3+ aortic regurgitation who are at high surgical risk. 
• Primary endpoints included 30-day safety and 1-year efficacy (all-cause mortality). 

What did the study show?  

The study demonstrated promising results for the JenaValve Trilogy™ system in treating high-risk surgical patients with severe aortic regurgitation. 

Key findings include: 

Primary safety and efficacy endpoints: 

• 2-year all-cause mortality: 15.4%, with most deaths non-cardiovascular in origin (7.4% cardiovascular mortality) 
• 2-year overall stroke rate: 6.4 % (2.3% disabling stroke) 
• 2-year new pacemaker rate: 26.7% (not much different from 30-day pacemaker rate of 24%) 
• 2-year major/life-threatening bleeding: 7.0% 
• 2-year surgery/intervention related to the device: 5.6% 

Hemodynamic Outcomes: 

• Sustained improvements in valve performance at 2 years (mean gradient <5 mmHg, EOA >2.5 cm²). 
• No cases of structural valve deterioration. 

Clinical Outcomes: 

• Significant improvements in NYHA functional class (68% Class III/IV at baseline vs. 90% Class I/II at 2 years). 
• Improved quality of life (KCCQ-OS score increased from 55.3 to 78.7 at 2 years). 

LV Remodeling: 

• Favorable LV volume and mass reductions sustained through 2 years. 

How good was the approach/methodology? 

The study methodology was robust in several aspects. Its multicenter design ensured diverse patient representation, and the follow-up included comprehensive clinical, echocardiographic, and quality-of-life assessments. Kaplan-Meier analysis added reliability to survival estimates.